Rabah A.T. Serya

Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidne Scaffolds as Cancer Targeting Agents

M. Abdel Aziz, Rabah A.T. Serya, Deena S. Lasheen et al. · Scientific Reports · 2016 · 174 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Surmounting the resistance against EGFR inhibitors through the development of thieno[2,3-d]pyrimidine-based dual EGFR/HER2 inhibitors

Sandra N. Milik, Amal Kamal Abdel‐Aziz, Deena S. Lasheen et al. · European Journal of Medicinal Chemistry · 2018 · 71 citations · Full text

Medicine, Medicinal Chemistry, Oncology +8

Thieno[2,3-d]pyrimidine based derivatives as kinase inhibitors and anticancer agents

Eman Z. Elrazaz, Rabah A.T. Serya, Nasser S. M. Ismail et al. · Future Journal of Pharmaceutical Sciences · 2015 · 69 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13

Novel quinoline-3-carboxamides (Part 2): Design, optimization and synthesis of quinoline based scaffold as EGFR inhibitors with potent anticancer activity

Rasha M. Aly, Rabah A.T. Serya, Amira M. El-Motwally et al. · Bioorganic Chemistry · 2017 · 56 citations

Pharmacy, Medicinal Chemistry, Pharmacology +13

Pyrazolo[3,4-d]pyrimidine based scaffold derivatives targeting kinases as anticancer agents

Nasser S. M. Ismail, Eslam M.H. Ali, Diaa A. Ibrahim et al. · Future Journal of Pharmaceutical Sciences · 2016 · 54 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15